SG11201605422TA - Heterocyclic modulators of lipid synthesis for use against cancer and viral infections - Google Patents
Heterocyclic modulators of lipid synthesis for use against cancer and viral infectionsInfo
- Publication number
- SG11201605422TA SG11201605422TA SG11201605422TA SG11201605422TA SG11201605422TA SG 11201605422T A SG11201605422T A SG 11201605422TA SG 11201605422T A SG11201605422T A SG 11201605422TA SG 11201605422T A SG11201605422T A SG 11201605422TA SG 11201605422T A SG11201605422T A SG 11201605422TA
- Authority
- SG
- Singapore
- Prior art keywords
- viral infections
- against cancer
- use against
- lipid synthesis
- heterocyclic modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461924520P | 2014-01-07 | 2014-01-07 | |
| PCT/US2015/010459 WO2015105860A1 (en) | 2014-01-07 | 2015-01-07 | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201605422TA true SG11201605422TA (en) | 2016-07-28 |
Family
ID=52394405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201605422TA SG11201605422TA (en) | 2014-01-07 | 2015-01-07 | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9994550B2 (en) |
| EP (1) | EP3092232B1 (en) |
| JP (1) | JP6522007B2 (en) |
| KR (1) | KR102335142B1 (en) |
| CN (1) | CN105980376B (en) |
| AU (1) | AU2015204907B2 (en) |
| BR (1) | BR112016015879B1 (en) |
| CA (1) | CA2935767C (en) |
| ES (1) | ES2913858T3 (en) |
| IL (1) | IL246463B (en) |
| MX (1) | MX2016008841A (en) |
| NZ (1) | NZ721780A (en) |
| RU (1) | RU2766087C2 (en) |
| SG (1) | SG11201605422TA (en) |
| WO (1) | WO2015105860A1 (en) |
| ZA (1) | ZA201604560B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170119786A1 (en) | 2011-03-08 | 2017-05-04 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
| EP2870150B1 (en) * | 2012-07-03 | 2019-06-19 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
| US10363249B2 (en) | 2014-08-15 | 2019-07-30 | 3-V Biosciences, Inc. | Fatty acid synthase inhibitor for use in the treatment of drug resistant cancer |
| CN105181844A (en) * | 2015-09-11 | 2015-12-23 | 江苏嘉逸医药有限公司 | Method for determining content and associated substances of sorafenib tosylate in high-performance liquid phase chromatography |
| JP2019533714A (en) | 2016-11-11 | 2019-11-21 | ３−ブイ・バイオサイエンシーズ・インコーポレイテッド３−Ｖ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | Heterocyclic modulators of lipid synthesis |
| CN106562961B (en) * | 2016-12-12 | 2017-09-01 | 深圳市宏辉浩医药科技有限公司 | A kind of pharmaceutical composition for treating cerebral infarction |
| BR112019011199A2 (en) * | 2016-12-12 | 2019-10-08 | Genentech Inc | method to treat an individual who has prostate cancer and kits |
| JP7300394B2 (en) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
| AU610083B2 (en) | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| US5928647A (en) | 1993-01-11 | 1999-07-27 | Dana-Farber Cancer Institute | Inducing cytotoxic T lymphocyte responses |
| RU2419612C2 (en) * | 2003-12-23 | 2011-05-27 | Астекс Терапьютикс Лимитед | Pyrazole derivatives as protein kinase modulators |
| TW200831092A (en) * | 2006-12-21 | 2008-08-01 | Astrazeneca Ab | Therapeutic agents |
| WO2008075077A1 (en) * | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Piperidine derivatives for the treatment of obesity |
| TW200833663A (en) | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
| MX369388B (en) | 2011-03-08 | 2019-11-07 | 3 V Biosciences Inc | Heterocyclic modulators of lipid synthesis. |
| US8871790B2 (en) * | 2011-03-08 | 2014-10-28 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
| EP2870150B1 (en) * | 2012-07-03 | 2019-06-19 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
-
2015
- 2015-01-07 US US15/110,154 patent/US9994550B2/en active Active
- 2015-01-07 WO PCT/US2015/010459 patent/WO2015105860A1/en active Application Filing
- 2015-01-07 KR KR1020167018178A patent/KR102335142B1/en active IP Right Grant
- 2015-01-07 RU RU2016127634A patent/RU2766087C2/en active
- 2015-01-07 MX MX2016008841A patent/MX2016008841A/en unknown
- 2015-01-07 SG SG11201605422TA patent/SG11201605422TA/en unknown
- 2015-01-07 AU AU2015204907A patent/AU2015204907B2/en active Active
- 2015-01-07 EP EP15700939.0A patent/EP3092232B1/en active Active
- 2015-01-07 NZ NZ721780A patent/NZ721780A/en unknown
- 2015-01-07 CA CA2935767A patent/CA2935767C/en active Active
- 2015-01-07 BR BR112016015879-2A patent/BR112016015879B1/en active IP Right Grant
- 2015-01-07 JP JP2016562737A patent/JP6522007B2/en active Active
- 2015-01-07 CN CN201580003786.5A patent/CN105980376B/en active Active
- 2015-01-07 ES ES15700939T patent/ES2913858T3/en active Active
-
2016
- 2016-06-26 IL IL246463A patent/IL246463B/en unknown
- 2016-07-05 ZA ZA2016/04560A patent/ZA201604560B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015204907B2 (en) | 2018-08-02 |
| JP2017502083A (en) | 2017-01-19 |
| KR102335142B1 (en) | 2021-12-06 |
| IL246463A0 (en) | 2016-08-31 |
| KR20160105416A (en) | 2016-09-06 |
| RU2766087C2 (en) | 2022-02-07 |
| CA2935767C (en) | 2023-01-31 |
| JP6522007B2 (en) | 2019-05-29 |
| CA2935767A1 (en) | 2015-07-16 |
| US20160326141A1 (en) | 2016-11-10 |
| AU2015204907A1 (en) | 2016-07-21 |
| CN105980376B (en) | 2019-03-22 |
| ZA201604560B (en) | 2019-01-30 |
| RU2016127634A3 (en) | 2019-06-17 |
| WO2015105860A9 (en) | 2016-02-04 |
| US9994550B2 (en) | 2018-06-12 |
| RU2016127634A (en) | 2018-02-09 |
| EP3092232B1 (en) | 2022-03-09 |
| BR112016015879A2 (en) | 2017-08-08 |
| ES2913858T3 (en) | 2022-06-06 |
| BR112016015879B1 (en) | 2022-06-14 |
| CN105980376A (en) | 2016-09-28 |
| NZ721780A (en) | 2022-01-28 |
| WO2015105860A1 (en) | 2015-07-16 |
| IL246463B (en) | 2022-04-01 |
| EP3092232A1 (en) | 2016-11-16 |
| MX2016008841A (en) | 2016-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283582A (en) | Modulators of ror-gamma | |
| HK1256599A1 (en) | Modulators of ror-gamma | |
| ZA201604560B (en) | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections | |
| EP3140310A4 (en) | Synthesis of boronate salts and uses thereof | |
| IL251477A0 (en) | Anti-ang2 antibodies and methods of use | |
| IL263050B (en) | Derivatives of sobetirome | |
| IL266505A (en) | Heterocyclic modulators of lipid synthesis | |
| HK1244445A1 (en) | Methods of using anti-ang2 antibodies | |
| EP3179994A4 (en) | Modified mito-metformin compounds and methods of synthesis and use thereof | |
| SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
| IL249434B (en) | Use of negative functional modulators of erythropoietin for therapy | |
| SG11201609739UA (en) | Derivatives of dolaproine-dolaisoleuine peptides | |
| HK1249425A1 (en) | Preparations of meta-iodobenzylguanidine and precursors thereof | |
| PT3143032T (en) | Novel derivatives of oxazaphosphorines and therapeutic uses thereof | |
| PL3174849T3 (en) | Synthesis of pyrrolidine derivatives | |
| TWM476518U (en) | Backplate of backpack | |
| ZA201704416B (en) | Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors | |
| TWM532871U (en) | Structure of medicine grinder | |
| EP3212202A4 (en) | Use of therapeutic agents | |
| SI3224253T1 (en) | Bis (sulfonamide) derivatives and their use as mpges inhibitors | |
| AU2014904330A0 (en) | Use of therapeutic agents | |
| AU2014901768A0 (en) | Heterocyclic compounds and use of same |